President Trump’s move to extract a 15% sales tax from Nvidia on semiconductors sold in China did nothing to damp investor enthusiasm for the world’s most valuable company.
As Trump has pressured drugmakers to lower the cost of medicines in the U.S., the pharma industry has coalesced behind a message of rebalancing what nations pay to better reflect the innovation and value of drugmaking.
The Boston-based AI/ML startup focuses on endocrine and cardiometabolic diseases and will use that expertise to generate new small molecule obesity medications for Lilly.
Vedanta is parting ways with 23 employees, or approximately 20% of its headcount, after Phase II data for microbiome therapy VE202 failed to demonstrate significant response rates in patients with ulcerative colitis.
In this episode of Denatured, BioSpace’s head of insights Lori Ellis discusses the ‘enormous implications’ of patent policy changes with Aaron Cummings and Anne Li of Brownstein Hyatt Farber Schreck.
A new study predicts the One Big Beautiful Bill Act will reduce federal taxes on average for individual taxpayers in every state, but the impact will differ.
The Internal Revenue Service’s Criminal Investigation unit is working on a new initiative for requesting financial records from banks to track illegal activity such as money laundering.
President Trump’s signature tax and spending bill is expected by most economists — and the Congressional Budget Office — to worsen U.S. deficits over the coming decade.